Literature DB >> 19955659

The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.

Il-Kang Na1, Sydney X Lu, Nury L Yim, Gabrielle L Goldberg, Jennifer Tsai, Uttam Rao, Odette M Smith, Christopher G King, David Suh, Daniel Hirschhorn-Cymerman, Lia Palomba, Olaf Penack, Amanda M Holland, Robert R Jenq, Arnab Ghosh, Hien Tran, Taha Merghoub, Chen Liu, Gregory D Sempowski, Melissa Ventevogel, Nicole Beauchemin, Marcel R M van den Brink.   

Abstract

Thymic graft-versus-host disease (tGVHD) can contribute to profound T cell deficiency and repertoire restriction after allogeneic BM transplantation (allo-BMT). However, the cellular mechanisms of tGVHD and interactions between donor alloreactive T cells and thymic tissues remain poorly defined. Using clinically relevant murine allo-BMT models, we show here that even minimal numbers of donor alloreactive T cells, which caused mild nonlethal systemic graft-versus-host disease, were sufficient to damage the thymus, delay T lineage reconstitution, and compromise donor peripheral T cell function. Furthermore, to mediate tGVHD, donor alloreactive T cells required trafficking molecules, including CCR9, L selectin, P selectin glycoprotein ligand-1, the integrin subunits alphaE and beta7, CCR2, and CXCR3, and costimulatory/inhibitory molecules, including Ox40 and carcinoembryonic antigen-associated cell adhesion molecule 1. We found that radiation in BMT conditioning regimens upregulated expression of the death receptors Fas and death receptor 5 (DR5) on thymic stromal cells (especially epithelium), while decreasing expression of the antiapoptotic regulator cellular caspase-8-like inhibitory protein. Donor alloreactive T cells used the cognate proteins FasL and TNF-related apoptosis-inducing ligand (TRAIL) (but not TNF or perforin) to mediate tGVHD, thereby damaging thymic stromal cells, cytoarchitecture, and function. Strategies that interfere with Fas/FasL and TRAIL/DR5 interactions may therefore represent a means to attenuate tGVHD and improve T cell reconstitution in allo-BMT recipients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19955659      PMCID: PMC2798682          DOI: 10.1172/JCI39395

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  62 in total

1.  Complete sequential regeneration of graft-vs.-host-induced severely dysplastic thymuses. Implications for the pathogenesis of chronic graft-vs.-host disease.

Authors:  T Ghayur; T A Seemayer; A Xenocostas; W S Lapp
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

2.  Early appearance of donor-type antigen-presenting cells in the thymuses of 1200 R radiation-induced bone marrow chimeras correlates with self-recognition of donor I region gene products.

Authors:  D L Longo; M L Davis
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

3.  Thymic involution in murine graft-versus-host reaction. Epithelial injury mimicking human thymic dysplasia.

Authors:  T A Seemayer; W S Lapp; R P Bolande
Journal:  Am J Pathol       Date:  1977-07       Impact factor: 4.307

4.  Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy.

Authors:  C L Mackall; T A Fleisher; M R Brown; M P Andrich; C C Chen; I M Feuerstein; M E Horowitz; I T Magrath; A T Shad; S M Steinberg
Journal:  N Engl J Med       Date:  1995-01-19       Impact factor: 91.245

5.  Ceacam1a-/- mice are completely resistant to infection by murine coronavirus mouse hepatitis virus A59.

Authors:  Erin Hemmila; Claire Turbide; Melanie Olson; Serge Jothy; Kathryn V Holmes; Nicole Beauchemin
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  T cell functional defect associated with thymid epithelial cell injury induced by a graft-versus-host reaction.

Authors:  M Seddik; T A Seemayer; W S Lapp
Journal:  Transplantation       Date:  1980       Impact factor: 4.939

7.  Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias.

Authors:  D Maraninchi; E Gluckman; D Blaise; D Guyotat; B Rio; J L Pico; V Leblond; M Michallet; F Dreyfus; N Ifrah
Journal:  Lancet       Date:  1987-07-25       Impact factor: 79.321

Review 8.  The functional and histological basis for graft-versus-host-induced immunosuppression.

Authors:  W S Lapp; T Ghayur; M Mendes; M Seddik; T A Seemayer
Journal:  Immunol Rev       Date:  1985-12       Impact factor: 12.988

9.  Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease.

Authors:  G A Holländer; B Widmer; S J Burakoff
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

10.  GITR activation induces an opposite effect on alloreactive CD4(+) and CD8(+) T cells in graft-versus-host disease.

Authors:  Stephanie J Muriglan; Teresa Ramirez-Montagut; Onder Alpdogan; Thomas W Van Huystee; Jeffrey M Eng; Vanessa M Hubbard; Adam A Kochman; Kartono H Tjoe; Carlo Riccardi; Pier Paolo Pandolfi; Shimon Sakaguchi; Alan N Houghton; Marcel R M Van Den Brink
Journal:  J Exp Med       Date:  2004-07-12       Impact factor: 14.307

View more
  38 in total

1.  Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Authors:  M Y Detrait; S Morisset; R Peffault de Latour; I Yakoub-Agha; R Crocchiolo; R Tabrizi; J-O Bay; P Chevalier; F Barraco; N Raus; S Vigouroux; L Magro; M Mohty; N Milpied; D Blaise; G Socié; M Michallet
Journal:  Bone Marrow Transplant       Date:  2014-11-03       Impact factor: 5.483

2.  The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease.

Authors:  Shan He; Fang Xie; Yongnian Liu; Qing Tong; Kazuhiro Mochizuki; Philip E Lapinski; Ram-Shankar Mani; Pavan Reddy; Izumi Mochizuki; Arul M Chinnaiyan; Shin Mineishi; Philip D King; Yi Zhang
Journal:  Blood       Date:  2013-10-18       Impact factor: 22.113

3.  CD4+ T cell-depleted lymphocyte infusion impairs neither the recovery of recipient thymus nor the development of transplanted thymus.

Authors:  Ming Shi; Ming Li; Yunze Cui; Lin Liu; Yasushi Adachi; Susumu Ikehara
Journal:  J Immunol       Date:  2013-02-04       Impact factor: 5.422

4.  Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells.

Authors:  Anne-Kathrin Hechinger; Kristina Maas; Christoph Dürr; Franziska Leonhardt; Gabriele Prinz; Reinhard Marks; Ulrike Gerlach; Maike Hofmann; Paul Fisch; Jürgen Finke; Hanspeter Pircher; Robert Zeiser
Journal:  Haematologica       Date:  2012-07-16       Impact factor: 9.941

5.  Rabbit antithymocyte globulin (thymoglobulin) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients.

Authors:  Il-Kang Na; Friedrich Wittenbecher; Mikalai Dziubianau; Anne Herholz; Angela Mensen; Désirée Kunkel; Olga Blau; Igor Blau; Eckhard Thiel; Lutz Uharek; Carmen Scheibenbogen; Kathrin Rieger; Andreas Thiel
Journal:  Haematologica       Date:  2012-07-16       Impact factor: 9.941

6.  Antibodies are back for thymic attack in cGVHD.

Authors:  Stefanie Sarantopoulos
Journal:  Blood       Date:  2016-05-05       Impact factor: 22.113

7.  Blockade of individual Notch ligands and receptors controls graft-versus-host disease.

Authors:  Ivy T Tran; Ashley R Sandy; Alexis J Carulli; Christen Ebens; Jooho Chung; Gloria T Shan; Vedran Radojcic; Ann Friedman; Thomas Gridley; Amy Shelton; Pavan Reddy; Linda C Samuelson; Minhong Yan; Christian W Siebel; Ivan Maillard
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

8.  Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD.

Authors:  Angela Mensen; Il-Kang Na; Ralf Häfer; Astrid Meerbach; Maria Schlecht; Marie-Luise Pietschmann; Bernd Gruhn
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-25       Impact factor: 4.553

9.  Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.

Authors:  Arnab Ghosh; Yildirim Dogan; Maxim Moroz; Amanda M Holland; Nury L Yim; Uttam K Rao; Lauren F Young; Daniel Tannenbaum; Durva Masih; Enrico Velardi; Jennifer J Tsai; Robert R Jenq; Olaf Penack; Alan M Hanash; Odette M Smith; Kelly Piersanti; Cecilia Lezcano; George F Murphy; Chen Liu; M Lia Palomba; Martin G Sauer; Michel Sadelain; Vladimir Ponomarev; Marcel R M van den Brink
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

10.  A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation.

Authors:  K Riesner; M Kalupa; Y Shi; S Elezkurtaj; O Penack
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.